Hematologic Malignancy
Plasma Cell Neoplasm
CI-CAN-00006438Explore in graph →
HematologicNon-malignant831 active trials25 approved drugs26 evidence items
Loading cancer entity…
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00006438Explore in graph →
Clinical trials
3,420 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT00320476 | VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates | completed | Phase 2 | 35 | Korean Multiple Myeloma Working PartyOTHER | 1 | May 6, 2008 | clinicaltrials |
| NCT00633542 | Maintenance Therapy After Thalidomide-Dexamethasone(ThaDD) for Multiple Myeloma(MM) | completed | Phase 3 | 103 | Università Politecnica delle MarcheOTHER | 1 | Mar 12, 2008 | clinicaltrials |
| NCT00001750 | Comparing Treatments for Multiple Myeloma | completed | Phase 2 | 32 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Mar 4, 2008 | clinicaltrials |
| NCT00257114 | Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability | completed | Phase 4 | — | Millennium Pharmaceuticals, Inc.INDUSTRY | 1 | Feb 11, 2008 | clinicaltrials |
| NCT00116441 | Vaccination in the Peripheral Stem Cell Transplant Setting for Multiple Myeloma | completed | Phase 1 / Phase 2 | 22 | Cell GenesysINDUSTRY | 1 | Dec 24, 2007 | clinicaltrials |
| NCT00086216 | Safety and Efficacy of Atiprimod for Patients With Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 30 | Callisto PharmaceuticalsINDUSTRY | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00165347 | Protein Tyrosine Kinases (PTK) in Multiple Myeloma | completed | Phase 2 | 10 | Dana-Farber Cancer InstituteOTHER | 1 | Dec 21, 2007 | clinicaltrials |
| NCT00001561 | Active Immunization of Sibling Bone Marrow Transplant Donors Against Purified Myeloma Protein of the Recipient Undergoing Allogeneic Bone Marrow Transplantation | completed | Phase 3 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 24, 2007 | clinicaltrials |
| NCT00145652 | Adjuvant I.V. Iron Therapy During Erythropoetin Treatment of Anemic Patients With Lymphoproliferative Disorders. | completed | Phase 3 | 66 | Sundsvall HospitalOTHER | 1 | Jul 30, 2007 | clinicaltrials |
| NCT00299780 | Safety Study of Parathyroid Hormone in Patients Needing Additional Stem Cell Mobilization. | completed | Phase 1 | 12 | Massachusetts General HospitalOTHER | 1 | Apr 24, 2007 | clinicaltrials |
| NCT00376883 | Pamidronate Prophylaxis in Multiple Myeloma 30 mg/Month Versus 90 mg/Month | completed | Phase 3 | 500 | Nordic Myeloma Study GroupOTHER | 3 | Jan 4, 2007 | clinicaltrials |
| NCT00399867 | Simvastatin as Inhibitor of Cell Adhesion Mediated Drug Resistance in Patients With Refractory Multiple Myeloma. | completed | Phase 2 | 30 | Ludwig-Maximilians - University of MunichOTHER | 0 | Dec 20, 2006 | clinicaltrials |
| NCT00358020 | Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients | completed | Phase 2 | 30 | University of Turin, ItalyOTHER | 1 | Dec 4, 2006 | clinicaltrials |
| NCT00396045 | Melphalan, Prednisone, and CC-5013 (Revlimid) as Induction Therapy in Multiple Myeloma | completed | Phase 1 / Phase 2 | 54 | University of Turin, ItalyOTHER | 1 | Nov 30, 2006 | clinicaltrials |
| NCT00400556 | ATRA Plus G-CSF for Mobilization of Hematopoietic Stem and Progenitor Cells | completed | Phase 1 | 6 | Peter MacCallum Cancer Centre, AustraliaOTHER | 1 | Nov 17, 2006 | clinicaltrials |
| NCT00037791 | Safety and Efficacy of (PN-152,243)/PN-196,444 in the Prevention of Thrombocytopenia | completed | Phase 3 | 180 | PfizerINDUSTRY | 3 | Nov 9, 2006 | clinicaltrials |
| NCT00300664 | A Randomized Trial of Human Growth Hormone (hGH) vs Placebo in Intensively Treated Haemato-Oncology Patients. | completed | Phase 2 / Phase 3 | 150 | Royal Marsden NHS Foundation TrustOTHER | 0 | Oct 13, 2006 | clinicaltrials |
| NCT00378222 | Autologous Transplantation for Multiple Myeloma | completed | Phase 3 | 324 | University of BolognaOTHER | 0 | Sep 19, 2006 | clinicaltrials |
| NCT00367185 | Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma | completed | Phase 3 | 500 | University Hospital, LilleOTHER | 1 | Aug 22, 2006 | clinicaltrials |
| NCT00096837 | A Study of Motexafin Gadolinium for the Treatment of Relapsed or Refractory Multiple Myeloma | completed | Phase 2 | 25 | Pharmacyclics LLC.INDUSTRY | 1 | Jun 8, 2006 | clinicaltrials |
| NCT00323505 | A Phase II Trial Comparing the Quality of Life, Tolerability and Toxicity of PEG Intron With INTRON® A in Patients With Multiple Myeloma | completed | Phase 2 | — | Royal Marsden NHS Foundation TrustOTHER | 1 | May 9, 2006 | clinicaltrials |
| NCT00301275 | Assessing Free Immunoglobulin Light Chains in Patients With Myeloma | completed | — | — | Royal Marsden NHS Foundation TrustOTHER | 1 | Mar 10, 2006 | clinicaltrials |
| NCT00078065 | Xcellerated T CellsTM in Patients With Multiple Myeloma | completed | Phase 2 | 30 | Xcyte TherapiesINDUSTRY | 1 | Nov 11, 2005 | clinicaltrials |
| NCT00036140 | Study of the Safety and Efficacy of an Investigational Drug in Adult Patients With Multiple Myeloma | completed | Phase 1 | — | PfizerINDUSTRY | 1 | Jun 24, 2005 | clinicaltrials |
Data updated 23 days agoSource updated May 6, 2008source: clinicaltrials